Cisneros-Poireth DA, Morales-Miranda AY, Ugalde-Aguilar H, Juárez-Navarrete L

Language: Spanish
References: 25
Page: 7-11
PDF size: 141.94 Kb.

ABSTRACT

Background: hair constitutes an integral part of our self and our identity. Androgenetic alopecia (aga) is a common hair loss disease, typically observed as a benign process with mostly cosmetic consequences. Recently the psychological, psychosocial and individual’s overall quality of life have been described.
Objective: to assess the impact of alopecia on quality of life and certain psychological domains such as depression and anxiety by using validated questionnaires.
Methods: sixty-five patients with androgenetic alopecia were studied and age and gender were reported. Every patient was evaluated to assess the impact of quality of life (dlqi), anxiety (Zung’s scale) and depression (Zung’s scale).
Results: sixty-five patients with androgenetic alopecia were studied. 80% (n = 52) male and 20% (n =13) female. The mean dlqi score was 13.21, findings indicate that in the majority of patients had a low qol. The mean in Zung’s depression scale was 59.63 and the mean in Zung’s anxiety scale was 62.4, this also shows psychological disturbance in the studied patients.
Conclusion: androgenetic alopecia, commonly known as male pattern baldness, is the most common type of progressive hair loss disorder in men, and the main reason for dermatological consultation. It is important that physicians consider the psychosocial impact of aga on diverse areas of patient’s lives. Physicians need to offer relevant treatment not just for hair loss, but also for emotional distress, and design consultations and interventions according to the patient, to improve physical and mental outcomes as well as qol in alopecia patients.

REFERENCES

1. Hamilton JB, Patterned loss of hair in man; types and incidence, Ann N Y Acad. Sci, 53:708-28.

2. Severi G, Sinclair R, Hopper JL, English DR, McCredie MRE, Boyle P y Giles GG, Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors, Br J Dermatol, 149:1207-13.

3. Hanneken S, Ritzmann S, Nothen MM et al., Androgenetic alopecia: current aspects of a common phenotype, Hautarzt 2003; 54(8):703-12.

4. Cash TF, The psychology of hair loss and its implications for patient care, Clin Dermatol 2001; 19(2):161-6.

5. Ellis JA, Sinclair R y Harrap SB, Androgenetic alopecia: pathogenesis and potential for therapy, Expert Rev Mol Med 2002; 4:1.

6. Nyholt DR, Gillespie NA, Heath AC y Martin NG, Genetic basis of male pattern baldness, J Invest Dermatol 2003; 121:1561.

7. Kuster W y Happle R, The inherinance of common baldness: two b or ot two b?, J Am Acad Dermatol 1984; 11:921.

8. Bergfeld WF, Androgenetic alopecia: an autosomal dominant disorder, Am J Med 1995; 98:95S.

9. Ellis JA, Stebbing M y Harrap SB, Genetic analysis of male pattern baldness and the 5alpha-reductase genes, J Invest Dermatol 1998; 110:849.

10. Birch MP y Messenger AG, Genetic factors predispose to balding and non balding in men, Eur J Dermatol 2001; 11:309.

11. Kaufman KD, Androgens and alopecia, Mol Cell Endocrinol 2002; 198:89.

12. Imperato-McGinley J y Zhu YS, Androgens and male physiology the syndrome of 5alpha reductase-2 deficency, Mol Cell Endocrinol 2002; 198:51.

13. Hamada K y Randall VA, Inhibitory autocrine factors produce by the mesenchyme derived hair follicle dermal papilla may be a key to male pattern baldness, Br J Dermatol 2006; 154:609.

14. Sawaya ME y Price VH, Different levels of 5 alpha-reductase type i and ii, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia, J Invest Dermatol 1997; 109:296.

15. Sawaya ME, Steroid chemistry and hormone controls during the hair follicle cycle. Ann NY Acad Sci 1991; 642:376.

16. Schmidt JB, Lindamaier A y Spona J, Hormonal parameters in androgenetic hair loss in the male, Dermatologica 1991; 182:214.

17. Gonul M, Cevirgen Cemil B, Hilal Ayyvaz H et al., Comparison of quality of life in patients with androgenetic alopecia, An Bras Dermatol 2018; 93(5):651-8.

18. Katoulis A, Liakou A, Kouris A et al., Quality of life and psychosocial impact of scarring and non-scarring alopecia in women Deutsch Dermatol Ges 2015; 1-5.

19. Davis DS y Callender VD, Review of quality of life studies in women with alopecia, Int J Womens Dermatol 2018; 4:18-22.

20. Russo PM, Fino E, Mancini C et al., hrqol in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psycosocial anxiety, jeadv 2019; 33:608-11.

21. Schmidt S, Fischer TW, Chren MM et al., Strategies of coping and quality of life in women with alopecia, Br J Dermatol 2001; 144:1038-43.

22. Nan-Lan Y, Huan T, Zhi-Qjang S et al., Illness perception in patients with androgenetic alopecia and alopecia areata in China, J Psychosomatic Research 2016; 86:1-6.

23. Sung-Hyub H, Ji-Won B, Won-Soo L et al., Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study, Ann Dermatol 2012; 24(3):311-6.

24. Gupta S, Goyal I y Mahendra A, Quality of life assessment with androgenetic alopecia, Int J of Trichology 2019; 11(4):147-52.

25. Williamson D, González M y Finlay AY, The effect of hair loss on quality of life, J Eur Acad Dermatol Venereol 2001; 15(2):137-9.